Saturday, November 22, 2008

Arpida Comments On FDA's Anti-infective Drugs Advisory Committee Outcome

Arpida (SWX: ARPN) announced that the Anti-infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous iclaprim, an antibiotic currently in development for the treatment of patients with complicated skin and skin structure infections (cSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). More at...

Mathematical models resolve controversy over nicotine addiction Increased use of computers to create predictive models of human disease is likely following a workshop organised by the European Science Foundation (ESF), which urged for a collaborative effort between specialists in the field. Human disease research produces an enormous amount of data from different sources such as animal models, high throughput genetic screening of human tissue, and in vitro laboratory experiments. More at...

A Mammography Workstation For Smaller Clinics

The data stored on this PACS is easily accessed from any mammography workstation that is also connected to the World Wide Web, allowing for genuine real-time collaboration among the members of the cancer patient's treatment team for less in terms of resources - both monetary and in terms of energy - than ever before. Each radiologist in the facility will appreciate the functionality of their mammography workstation, while those in accounting will appreciate the value and the economy of the entire system.

Mechanisms Of Cardiovascular Disease And Cancer Give Clues To New Therapies

Cardiovascular conditions leading to heart attacks and strokes are treated quite separately from common cancers of the prostate, breast or lung, but now turn out to involve some of the same critical mechanisms at the molecular level. This in turn provides clues to more effective therapies for both cancer and cardiovascular diseases, but requires researchers in these distinct fields to come together. Read more ...